Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs
for Earthquake Disaster Areas
BEIJING, June 16 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA),
a leading provider of vaccines in China, today announced that the Shanxi
Center for Disease Control and Prevention (CDC) ordered 257,100 doses of
Healive(R), the inactivated hepatitis A vaccine manufactured by Sinovac. On
the same day, the Gansu CDC ordered 47,000 doses of Bilive(R), a combined
hepatitis A and hepatitis B vaccine manufactured by Sinovac. The vaccine
purchased by the local CDCs will be utilized to inoculate children in the
disaster zones following the May 12th earthquake to prevent the infectious
disease. Concurrently, Sinovac donated an additional 8,000 doses of Healive(R)
to affected areas in the Shanxi Province. Sinovac's clinical experts were
dispatched to the inoculation area to assist the local CDCs with immunization.
Mr. Weidong Yin, Chairman, CEO and President of Sinovac, commented, "The
delivery of additional vaccines to the earthquake area reflects our consistent
commitment to contribute to improving human health across China. Sinovac's
highly efficient manufacturing operations enable us to play a significant role
in supplying vaccines for the prevention of infectious diseases during
emergency situations. Our established post sales service programs allow for
the timely distribution of vaccines to the local CDC doctors in earthquake
disaster areas."
As previously announced, the Beijing municipal government purchased on
June 11 80,000 doses of Bilive(R), the combined inactivated hepatitis A and B
vaccine manufactured by Sinovac, and the vaccines were delivered to disaster
area in Gansu Province. Sinovac donated on May 19 to the earthquake disaster
area 50,000 doses of Healive(R), of which 10,000 doses were sent to the Gansu
province. On May 22, the Ministry of Health purchased approximately RMB 20
million of Healive(R).
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's
commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined
hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is
currently developing Universal Pandemic Influenza vaccine and Japanese
encephalitis vaccine. Additional information about Sinovac is available on its
website, http://www.sinovac.com . To be added to our distribution list, please
email: info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors/Media:
Stephanie Carrington / Janine McCargo
The Ruth Group
Tel: +1-646-536-7017/7033
Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.
Helen G. Yang of Sinovac Biotech Ltd., +86-10-8289-0088 x871, or
+86-10-6296-6910, or info@sinovac.com; or Investors/Media: Stephanie
Carrington / Janine McCargo of The Ruth Group, +1-646-536-7017/7033, or
scarrington@theruthgroup.com / jmccargo@theruthgroup.com
